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A B S T R A C T
Thiosulfate sulfurtransferase (TST, EC 2.8.1.1), also known as Rhodanese, is a mitochondrial enzyme which
catalyzes the transfer of sulfur in several molecular pathways. After its initial identification as a cyanide de-
toxification enzyme, it was found that its functions also include sulfur metabolism, modification of iron‑sulfur
clusters and the reduction of antioxidants glutathione and thioredoxin. TST deficiency was shown to be strongly
related to the pathophysiology of metabolic diseases including diabetes and obesity. This review summarizes
research related to the enzymatic properties and functions of TST, to then explore the association between the
effects of TST on mitochondria and development of diseases such as diabetes and obesity.
1. Introduction
Thiosulfate sulfurtransferase (TST), is an abundant mitochondrial
enzyme known to catalyze the in vitro transfer of a sulfur atom from a
sulfane-containing donor to a nucleophilic acceptor [1,2]. TST was first
characterized in 1933, with the assumption that its enzymatic function
was solely required for the cyanide detoxification. At the time, sodium
thiosulfate was known to be a sulfur donor for TST-catalyzed cyanide-
sulfonation [1]. For several decades, the enzyme was used in toxicology
against cyanide-intoxication and for detection and quantification of
cyanide levels in blood [3]. As more of its characteristics are un-
covered/revealed, the critical function of TST in regulating cellular
homeostasis becomes apparent, in particular in situations of vulner-
ability such as cellular stress that ultimately result in human diseases
[4,5].
The first part of this review describes the structural and biochemical
characteristics of sulfurtransferases, followed by a detailed analysis of
TST's intracellular physiological functions. The second part of the re-
view provides an overview of the molecular pathways involved in
diseases associated with alteration of TST expression and function.
2. Structural characteristics of TST
The family of eukaryotic sulfurtransferases is divided into three
classes. TST belongs to the well-characterized tandem-domain sulfur-
transferases, the other two classes are single-domain and multidomain
sulfurtransferases [6]. In addition to TST, there is one other known
tandem-domain sulfurtransferase: mercaptopyruvate sulfurtransferase
(MST). MST and TST were found to share a high sequence homology,
which led to the notion that these enzymes might be evolutionarily
related [7]. Studies in 3-MST knock out mice shows that TST can serve
as a back-up system for 3-MST [8].TST is solely localized at the mi-
tochondrial sites [9], whereas MST is localized in both cytoplasm and
mitochondria [10].
Human TST (hTST) consists of 297 amino acids with a molecular
weight of 33.4 kDa. BLAST analysis shows that hTST (Fig. 1a) is 90%
identical to extensively studied bovine TST (Fig. 1b). The crystal
structure of both TST isoforms consists of two similar globular domains
[11]. These domains are connected by a tether region and are asso-
ciated by strong hydrophobic interactions. The sequence homology
between the two domains however is rather poor [12,13]. The slightly
smaller C-terminal domain hosts the active site, which is located near
the interdomain surface [14] and the Cys-248 (247 in bovine TST [15])
is located in the active site cavity being directly involved in the enzy-
matic reaction. The expected large conformational change during cat-
alysis has not yet been characterized structurally, likely due to the
structural flexibility involved [2,16].
There are different structural conformations of TST, transitions
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between which being affected by substrate interaction [17]. Although
the enzyme is a homogeneous single-polypeptide chain, it is separable
by electrophoresis into four forms which differ in net surface charge.
The most positively charged form is the most abundant in vivo form
[18]. The reason for this variability in net surface charge of TST is not
well known, although it is suggested to be a consequence of various
structural relaxation events that occur outside the catalytic cycle, as
discussed in Section 4.1 [19]. The occurrence of a conformational
change after oxidation results in both an increased exposure and also
flexibility of the interdomain tether [20]. Oxidized TST adopts a new
conformation containing extensively exposed apolar surfaces and this
new form can result in both noncovalent and disulfide-bonded ag-
gregates [21].
The other two classes: single-domain and multi-domain sulfur-
transferases, have received less attention. In humans, three single-do-
main sulfurtransferases have been characterized, named TST-like do-
mains (TSTD1, TSTD2 and TSTD3). In TSTD1, an enzyme known to
contribute to cyanide detoxification, contains an active site character-
ized by catalytic cysteine Cys-32. Similar to the enzymes TST and MST,
TSTD1 also catalyzes sulfur transfer to cyanide [22]. Recombinant
human TSTD1 utilizes thiosulfate as a sulfur donor. TSTD3 lacks a re-
active cysteine, and is therefore highly unlikely to catalyze sulfur
transfer on its own, and TSTD2 has not yet been fully characterized.
Multi-domain sulfurtransferases are probably not involved in sulfide
signaling [6].
3. Enzymatic activity of TST
In sulfurtransferases, residues on an active-site loop containing the
catalytic cysteine, are predicted to confer substrate specificity [24]. In
TST specifically, the positive charges at the proximal arginine and ly-
sine residues in the CRKGVT motif are predicted to interact with the
negative charges on the substrate, such as the oxygen atoms in
thiosulfate. Although the catalytic cysteine is the only cysteine strictly
required for enzymatic activity, mutations of noncatalytic cysteines
result in destabilization of the native structure of the enzyme [25]. The
electrophilic site of TST is dependent on metal ions. Various metal ions
can serve as the electrophilic site of TST; for instance, when oxalate is
used to bind calcium ions, TST is completely inhibited provided that
magnesium levels are low [26]. TST is inhibited reversibly and com-
petitively with respect to thiosulfate by most anions at rather high
concentrations. The most active inhibitors are aromatic anions [15].
Human MST has several important active site residues also seen in TST.
The catalytic cysteine (Cys246), and the arginine which defines the
substrate binding site (Arg185) are conserved. Two other active site
residues (Arg247 and Lys248) are not conserved in MST [7]. Compar-
ison of the active-site loop residues in TSTD1 versus TST and MST re-
veals significant stereo-electronic differences. The active site of TSTD1
is relatively surface-exposed, whereas it resides in a deep cleft in TST
and MST, between the interdomain interfaces. For TSTD1, the shallow
active-site pocket might promote interactions with larger substrates,
namely proteins [22].
The catalytic activity of TST proceeds via double displacement
mechanism: first the reactive cysteine in the active site (Cys247) ac-
cepts a sulfane sulfur from a suitable donor (e.g. thiosulfate) thereby
forming a persulfide intermediate state (as shown in Fig. 2). The per-
sulfide sulfur is subsequently transferred from the enzyme to a nu-
cleophilic acceptor (e.g. cyanide), recovering the native enzyme form.
The estimated Km of TST for thiosulfate is 39.5 mM, and its Km for
cyanide is 29 mM [27]. The reaction is non-specific, as various sulfur
donors and acceptors can interact with TST. Although many of these
interactions are to some degree reversible, the sulfonation of cyanide is
not. TST is able to mediate both reactions, of catalyzing sulfane
transfer, and interconverting various forms of sulfanes [3]. These in-
clude inorganic thiosulfate, organic thiosulfonates (RS(O2)S−) and
persulfides (RSS−).
Fig. 1. The generalized reaction catalyzed by TST based on Nandi et al. [23].
Fig. 2. a: Predicted three-dimensional structure for hTST. b: Crystal structure of bovine TST as an enzyme-substrate intermediate]. The three dimensional structure of
bovine TST was obtained from the Protein Data Bank (www.rcsb.org). Homology modelling of human TST was performed using the SWISS-MODEL facility (http://
swissmodel.expasy.org/SWISS-MODEL.html).
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4. Sulfurtransferase cellular functions of TST
Understanding of the sulfurtransferase function has broadened
considerably in the 85 years after initial characterization of TST and
MST. Their widespread occurrence suggests a vital role
[7,15,26,27,28,30,29,31]. In addition to the cyanide detoxification,
several additional functions of TST have been suggested [31,32]. TST
could modulate respiratory activity in the mitochondria through the
iron‑sulfur centers in redox-capable proteins [33–35]; it interacts with
mitochondrial antioxidant systems [22,23,36], and it may regulate in-
organic sulfide metabolism [37]. A summary of the most important
interactions of TST and peripheral enzymes is shown in Fig. 3 and
Table 1.
4.1. Phosphorylation model and respiratory function of TST
TST can be phosphorylated, likely as the result of cytoplasmic cel-
lular signaling [33]. The predicted phosphorylation site (serine 124 in
bovine TST) is accessible in unsulfurylated TST, yet rendered in-
accessible in the persulfide intermediate form. The consequence of
phosphorylation is a conformational change in the enzyme, which
brings the side chain containing cysteine 247 into proximity with either
Cys-254 or Cys-263 [38]. In presence of an electrophile acceptor these
cysteines can form a disulfide bridge, rendering the phosphorylated TST
incapable of metabolizing sulfane sulfur donors. Instead, oxidized
phosphorylated TST can extract labile sulfide from an iron‑sulfur center
of the respiratory chain. The labile sulfide reduces the newly-formed
disulfide bridge, creating an enzymatic persulfide. This persulfide sulfur
is transferred to a sulfur acceptor, after which the phosphorylated TST
either undergoes oxidation to accept more labile sulfide or is depho-
sphorylated by a yet unknown protein phosphatase. The sulfur in the
iron‑sulfur centers of complexes III and IV serves to stabilize the ir-
on‑sulfur centers by which the electron transport chain (ETC) proteins
execute their function. Therefore, the removal of a sulfur by phos-
phorylated TST would result in a decrease in the rate of electron
transport and ATP production. Conversely, dephosphorylated TST
could increase the rate of electron transport and ATP production, by
catalyzing the reverse reaction and mobilizing sulfur for the formation
or repair of iron‑sulfur clusters [39]. As such, TST was shown to interact
with enzymes of oxidative metabolism, like succinate dehydrogenase
[34], NADH dehydrogenase [40], xanthine oxidase [41], and NADH
nitrate reductase [42]. Besides the rate of electron transport, reduced
Fig. 3. Construction of iron‑sulfur complexes as active redox-
centers is (co-)dependent on TST activity, phosphorylated TST
(represented as TST-P) is proposed to catalyze the reverse
reaction [39]. TST phosphorylation is likely governed by cy-
toplasmic signaling, the details of which are yet unknown
[33].
Table 1
Kinetic parameters reported for sulfurtransferase activity by TST, MST, TSTD1, glutathione (GSH), and sulfide:quinone oxidoreductase (SQR). C.I = Complex I,
NADH dehydrogenase. C.II = Complex II, succinate dehydrogenase. XO = xanthine oxidase. NIR = nitrate reductase (NADH dependent). 2-ME = 2-mercap-
toethanol. DTT = dithiothreitol. DHLA = dihydrolipoic acid. TRX = thioredoxin. Interactions marked with * have been reported, but not yet characterized.
Donor Acceptor Km donor Km acceptor Vmax Kcat Hill coeff. Ref.
μM μM μmol∗min−1∗mg−1 s−1
hTST
S2O32− CN (39.5 ± 2.5) ∗ 103 29 ± 4 ? 910 ? [27]
S2O32− GSH 340 ± 50 21 ± 0.4 1.2 ± 0.02 0.67 2.3 ± 0.2 [27]
S2O32− Cys 350 ± 60 20 ± 0.5 13 ± 0.3 7.4 ? [27]
S2O32− Hcy 300 ± 100 20.5 ± 1.9 15.5 ± 0.9 8.7 ? [27]
CH3S(O2)S− TRX (20 ± 4) ∗ 103 0.0185 ± 0.002 88 ± 5 * * [48]
CH3S(O2)S− DTT * 16 * * * [48]
CH3S(O2)S− Lipoate * 10 * * * [48]
CH3S(O2)S− SO32− 450 ± 4 0.06 ± 0.01 609 ± 25 389 * [27]
S2O32− C.I * * * * * [40]
S2O32− C.II * * * * * [34]
S2O32− XO * * * * * [41]
S2O32− NIR * * * * * [42]
hMST
3-MP 2-ME 130 ± 30 108 ± 16 417 ± 38 229 * [47]
3-MP DTT 26 ± 5 4.6 ± 0.5 11 ± 2 6.1 * [47]
3-MP CN 350 ± 62 6 ± 1 4.3 ± 0.3 2.4 * [47]
3-MP DHLA 25 ± 6 4.4 ± 0.3 3.1 ± 0.3 1.7 * [47]
3-MP Cys 22 ± 2 4.1 ± 0.6 2 ± 0.2 1.1 * [47]
3-MP Hcy 30 ± 0.2 12.5 ± 1.6 1.6 ± 0.2 0.8 * [47]
3-MP GSH 20 ± 0.4 28 ± 2 0.61 ± 0.04 0.3 * [47]
3-MP TRX 350 ± 62 2.5 ± 0.4 ∗ 10−3 2.3 ± 0.2 1.3 * [47]
TSTD1
S2O32− CN (22 ± 3) ∗ 103 0.270 ± 0.02 * 0.52 * [22]
S2O32− GSH (17 ± 1) ∗ 103 11 ± 1 * 0.432 1.8 ± 0.2 [22]
S2O32− Cys (14 ± 2) ∗ 103 13.7 ± 1.9 * 0.7 1.9 ± 0.1 [22]
S2O32− Hcy (18 ± 1) ∗ 103 10.7 ± 0.4 * 0.61 2 ± 0.1 [22]
S2O32− TRX 22 ∗ 103 (1.7 ± 2) ∗ 10−3 * 0.116 * [22]
SQR
– H2S – 0.32 ± 0.04 95 ± 5 74 – [49]
H2S CoQ * 0.019 * * * [49]
H2S GSH 10 22 ± 3 144 ± 12 113 1.10 ∗ 107 [27]
H2S Cys 5 23 ± 4 120 ± 5 94 1.90 ∗ 107 [27]
H2S Hcy 7 22 ± 3.5 117 ± 6 92 1.30 ∗ 107 [27]
H2S SO32− 13 0.22 ± 0.02 476 ± 16 373 2.90 ∗ 107 [27]
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availability of iron‑sulfur centers also results in an increase of protein
reduction, which increases the formation of superoxide anions [43].
The iron‑sulfur clusters of ferrodoxins, succinate dehydrogenase, and
mitochondrial NADH dehydrogenase can be reconstituted by incuba-
tion with TST, a sulfur donor and acceptor, and an iron source
[6,34,40,44]. In the course of its interaction with enzymes of the ETC,
TST would directly control mitochondrial respiratory activity.
The phosphorylation state of the TST enzyme could be a highly
dynamic process with a steady-state level of modification of iron‑sulfur
centers in the ETC. Teleologically, TST phosphorylation represents a
mechanism by which mitochondria adjust the rate of oxidative meta-
bolism in response to energetic demand.
4.2. Interaction of TST with antioxidant systems
Living organisms are equipped with a variety of antioxidant sys-
tems, which coordinate removal of reactive oxygen species (ROS) and
reactive nitrogen species (RNS). In mammalian cells, there are two
major thiol-dependent antioxidant systems, the thioredoxin system and
the glutathione (GSH) system. GSH is the most abundant non-protein
thiol in the mammalian cells [45]. GSH can accept its sulfurs from
human sulfide:quinone oxidoreductase (SQR) or TST forming glu-
tathione persulfide (GSSH), which in turn can reduce thioredoxin
(TRX). TSTD1 and MST can also directly feed sulfurs into both anti-
oxidant systems (as shown in Table 1). Therefore, increased activity of
sulfurtransferases directly and indirectly increases the activity of ROS
scavengers [14,22]. TST is also capable of using GSSH as a sulfur donor,
possibly using GSSH as a source for the sulfonation of cyanide, or the
interconversion of sulfane sulfurs [3,46]. The ability of TST to catalyze
the sulfur transfer both forward and reverse is possibly governed by the
phosphorylation state of the enzyme (Section 4.1). In this case, the
kinetic behavior of these enzymes implies that there is flow of sulfide
from SQR via GSH to TST (Fig. 4). The reverse reaction is not catalyzed
by any other enzyme from the sulfurtransferase family [14]. The GSH
system participates in the defense against oxidative stress via ROS-
scavenging by glutathione peroxidase (Grx). It also has a regulatory
function, through the reversible coupling of GSSH to proteins under
conditions of oxidative stress.
4.3. TST and selenium metabolism
Besides transferring sulfur, TST plays a role in selenium metabolism.
The oxidized form of TST can bind selenium at a 1:1 molar ratio in
vitro, leading to the formation of the stable perselenide form of TST
[66]. TST has been proposed to be critical in generation of the reactive
form of selenium for synthesis of selenophosphate (SePO3). SePO3 is the
active selenium-donor compound required for synthesis of SeCys-tRNA,
precursor of selenocysteine in selenoenzymes. Selenoenzymes may fa-
cilitate the removal of hydrogen peroxide by GSH, as well as providing
reducing equivalents to TRX, indicating its role in both antioxidant
systems. Furthermore, they are required for both activation and in-
activation of thyroid hormones, and they also facilitate ER-associated
protein degradation [67]. By merit of these functions, selenoenzymes –
and by extension TST – play an important role in immunoregulation. In
a manner that is not yet fully understood, selenoenzymes may ad-
ditionally have pro- and anticancer activities [67].
The role of TST in sulfur and selenium metabolism, the regulation of
respiratory function and the interaction with antioxidant systems, make
a case for TST to be a tightly regulated link between diverse mi-
tochondrial processes. Consistent with the diversity of mechanisms, an
imbalance in TST activity or availability may have implications for an
equally diverse range of pathological processes.
4.4. The thioredoxin system
The thioredoxin system, a disulfide reductase system, is comprised
of TRX, NADPH and thioredoxin reductase (TRXr). Like the glutathione
system, it has many functions, including ROS-scavenging, DNA synth-
esis and H2S-signaling. The antioxidant activity of the TRX system is
mainly accomplished by the reduction of periredoxins (Prx), methio-
nine sulfoxide reductases (MSR), and several redox-sensitive tran-
scription factors. Reduced Prx isoforms can scavenge hydrogen per-
oxide (H2O2), peroxide (ROOH), and peroxynitrite (ONOO−) radicals.
Besides providing reducing equivalents to antioxidant enzymes, TRX is
involved in redox-signaling by regulating the activity of redox-sensitive
transcription factors. TRX is also found to be critical for DNA synthesis
and repair through the reduction of ribonucleotide reductase [50], as
well as dealing with oxidative stress [51]. Both the persulfidated and
thiol forms of TRX can be respectively oxidized and reduced, by all
members of the sulfurtransferase family [22,47]. TRX may also be ac-
tivated through H2S-signaling [52–54].
The activity of many redox-related transcription factors and sig-
naling factors are mediated by both the glutathione and thioredoxin
systems [45,55]. The activity of transcription factors such as nuclear
factor-κβ (NF-κB) and thyroid-specific promotors is affected by the
cellular redox environment. If there is a lack of reduced GSH or TRX,
the transcription factors lose their ability to bind to DNA efficiently
[55,56]. Conversely, transcription factors such as activator protein-1
(AP-1) and heme oxygenase are activated with GSH depletion [55]. The
antioxidant systems also mediate signaling factors such as apoptosis
signal-regulating kinase 1 (ASK1) and protein tyrosine phosphatase 1b
(PTP1B). Unbound ASK1 increases the level of p38 MAPK pathway
activity. Reduced TRX as well as glutaredoxins have the ability to in-
hibit ASK1 and its release [57,58]. By merit of its interaction with
antioxidant systems, ASK1 functions as a sensor for mitochondrial ROS-
production. Glutathione can also react with the active site cysteine in
PTP1B, as a form of reversible inhibition. This process, called glu-
tathionylation, is named as an important regulator in PTP1B activity in
vivo [59]. TRX is able to reactivate oxidized PTP1B, allowing it to act as
a modifier in growth-factor induced signaling [60].
Thioredoxin system activity can be linked quite directly to disease
susceptibility, through thioredoxin interacting protein (TXNIP), which
downregulates TRX activity. Knocking out TXNIP causes the cell to
change its glucose metabolism to increase anaerobic glycolysis and
release TRX in order to increase ROS-scavenging [61–65]. High levels
of TXNIP are suggested to induce high glucose-induced ROS generation
and mitochondrial pathway apoptosis in β-cells, and it is therefore
closely linked to glucose-intolerance and diabetes. Conversely,
knocking out TXNIP causes the cell to change its glucose metabolism to
increase anaerobic glycolysis and release TRX in order to increase ROS-
scavenging. TXNIP deficiency and TRXr and TRX overexpression is
linked to several forms of cancer, as cancer cells appear to rely on the
TRX system for ROS-scavenging [45]. Therefore, through the thior-
edoxin system, antioxidant function may be linked to both diabetes and
cancer. A direct link between thioredoxin and TST activity has not yet
been shown.
5. Clinical associations with TST activity
The availability and activity of TST is closely linked to metabolic
diseases where it has a beneficial role through effects on mitochondrial
activity and increasing antioxidants. It may also play a positive role in
colonic diseases and neuropathy where it functions primarily by de-
creasing H2S and cyanide, respectively. Analysis of the function and
interactions of TST will hopefully lead to new insights in a wide array of
diseases. In the following paragraphs we will discuss some examples.
5.1. TST and diabetes mellitus
TST is currently the only gene that is validated as a positive pre-
dictor in metabolic health, displaying a distinct negative correlation
with the development of adiposity and insulin resistance [68].
P.D. Kruithof, et al. BBA - Molecular Basis of Disease 1866 (2020) 165716
4
Treatment with thiosulfate as the main substrate for TST, has been
found to improve the impaired glucose-uptake symptoms of diabetic
mice, and reverse the effects of insulin resistance on 3T3-L1 adipocytes.
Morton et al. [68] found analogous data in human adipose tissue, where
TST expression correlated negatively with body mass index (BMI) and
positively with levels of GLUT4, insulin receptor substrate 1 (IRS1) and
peroxisome proliferator activated receptor gamma (PPARG). TSTs
quantitative trait locus was the only one found to have a strong nega-
tive correlation with fat mass and plasma glucose levels while having a
positive correlation with adiponectin expression. Adiponectin is a well-
recognized antidiabetic protein hormone [69]. This indicates that TST
is a prime candidate as a drug target against obesity and diabetes.
As discussed in Section 4, TST may be the switch between two
important mitochondrial systems. Both of these systems could posi-
tively influence diabetic symptoms. Firstly, TST is able to influence
respiratory capacity through interaction with the iron‑sulfur centers in
the electron transport chain suggesting a direct link of TST to glucose
intolerance. Secondly, TST is able to feed electrons into the antioxidant
systems. Since diabetes appears strongly influenced by inflammation
[70], increased activity of antioxidant systems could be vital to obesity
resistance.
5.2. TST and colonic diseases
Impaired or deficient sulfur metabolism may play a major role in the
progression of common colonic diseases. TST is likely to be the re-
sponsible enzyme for H2S metabolism in rectal mucosa [71]. Expression
of TST in colon mucosa is often markedly reduced in patients with ul-
cerative colitis and colon cancer when compared to normal mucosa,
although the evidence is not completely consistent [72]. This decrease
in TST activity corresponds with the development of colitis, and is
followed by an elevation of TST activity in erythrocytes [71–73].
Conversely, mucosal healing was associated with an increased TST gene
expression. It is not clear whether this abnormality is a primary defect
or the result of inflammation. The activity and expression of TST in the
colonic mucosa can be significantly increased by induction with either
butyrate or sulfide, which protects the mucosa from sulfide-induced
cytotoxicity. The capacity of the mucosa to oxidize butyrate is
Fig. 4. a: Sulfur oxidation pathway in the human mitochon-
dria [22,27,33,47]. The cyanide detoxification reaction was
omitted from this subfigure. b: Cyanide sulfonation reaction
schematically represented. ES represents the native enzyme,
and ESS represents the persulfidated enzyme [23]. The kinetic
parameters observed for the interactions displayed, are de-
tailed in Table 1.
Abbreviations in alphabetical order: CI–CIV: mitochondrial
electron transport complexes 1–4, CBS: cystathione beta
synthase, CoQ: coenzyme Q, CSE: cystathionine gamma-lyase,
Cys: cysteine, GST: glutathione, MST: mercaptopyruvate sul-
furtransferase, 3-MP: 3-mercaptopyruvate, NIR: nitrite re-
ductase, PDO: persulfide deoxygenase, SO: sulfite oxidase,
SQR: sulfide:quinone oxidoreductase, TST: thiosulfate sulfur-
transferase, TSTD1: thiosulfate sulfurtransferase-like domain
1, XO: xanthine oxidase.
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decreased in patients with ulcerative colitis. Failure of colonocytes to
differentiate appropriately may increase the exposure of colonocytes
and other cells in the crypt to the toxic effects of luminal H2S. This
could result in cell death and the inflammation seen in ulcerative co-
litis. Persistent insult may result in the genetic changes seen in color-
ectal cancer. Elevations in H2S-levels can be caused by a disturbed
balance of sulfate-reducing bacteria, and inadequacies in sulfur detox-
ification. This may aggravate inflammatory bowel disease and it could
ultimately progress to colorectal cancer [9,71,74]. Besides colonic
diseases, there is also evidence that the reduction of TST activity in the
intestinal mucosa is an age-related process. Deterioration of mi-
tochondrial capacity and decline of antioxidant activity are likely to
play a role the aging of colonic epithelium [75]. Polymorphic variations
that are distant from the active site might influence sulfurtransferase
reactive efficiency, which might prove important in understanding the
varying susceptibility to inflammatory bowel diseases.
5.3. TST and other diseases
There is some evidence of TST activity playing a role in several
other diseases, such as Lebers Hereditary Optic Disease (LHOD)
[76–78], human gliomas [36] and hemodialysis patients [43]. Mi-
tochondrial dysfunction has also been linked to neuro-inflammation in
LHOD [79]. In LHOD, one study found a marked decrease in the TST
expression and specific activity in liver biopsies [75], and it is suggested
that the impairment of the cyanide detoxification pathway plays a role
in the disease progression. Another study found a significant size in-
crease in the mitochondria in anterior tibial muscle from LHOD patients
[77]. The enlargement could be attributed to a compensation for a
metabolic defect. The activity of TST in rectal mucosa was also found to
be six fold lower in patients with LHOD, suggesting that TST deficiency
either causes LHOD or is directly involved in its development. This
hypothesis was later disputed by Whitehouse et al. [80], who found no
evidence of quantitative or qualitative defects on the liver TST isozyme
patterns of subjects with LHOD. To our knowledge, the studies into
TSTs role in human gliomas and hemodialysis mortality have not re-
ceived follow-up.
5.4. Thiosulfate treatment
Some information about TSTs effect in vivo can be inferred based on
the effects of clinical treatment with its substrate: thiosulfate. In healthy
patients, thiosulfate is excreted renally and hepatically in equal pro-
portions [81]. Metabolism of thiosulfate in humans is mostly based on
sulfurtransferase activity (primarily TST and TSTD1, see Section 4).
Historically, thiosulfate has been used clinically as an antidote for cy-
anide poisoning. In recent years however, sodium thiosulfate has been
successfully used as an off-label drug in calciphylaxis. Calciphylaxis is
an uncommon complication in patients with end-stage kidney disease
on dialysis which is associated with high mortality. Thiosulfate could
combine with insoluble tissue calcium salts to form highly soluble
calcium thiosulfate [82]. The fast rate of plasma clearance implies that
the effect of thiosulfate on chelating vascular calcification is perhaps
less important than initially thought or that the by-products of its me-
tabolism are more therapeutically active than thiosulfate itself. This
implies that sulfurtransferase activity is required for the therapeutic
effect of thiosulfate. In addition to calciphylaxis treatment, thiosulfate
is thought to restore endothelial homeostasis by increasing nitric oxide
synthase activity and regenerating GSH through sulfurtransferase ac-
tivity. It is also found to be protective in experimental cardiac ischemia
and angiotensin-II induced cardiac and renal disease [83–85] En-
dogenous thiosulfate has been hypothesized to act as a precursor in
H2S-sigaling, as multiple enzymes may facilitate the reaction from
thiosulfate to H2S. Beneficial effects of H2S have been extensively re-
viewed elsewhere [86–89] When thiosulfate is dissolved in tissue in
very high concentrations, it inhibits the mitochondrial cytochrome
complex IV in addition to directly causing profound sulfide-generated
oxidative stress [81]. This effect contrasts its ability to reduce oxidative
stress in lower concentrations, as it may feed sulfur and reducing
equivalents to the antioxidant systems via TST. Interestingly, another
sulfur compound derived from garlic, i.e. diallyl trisulfide, has recently
shown to not only increase MPST but also TST in cultured cells [90].
6. Concluding remarks and outlook
This review demonstrates TSTs diverse functionality and clinical
relevance. When summarizing the academic developments of the past
85 years, it becomes apparent that despite the wide range of studies, the
description of TSTs characteristics is composed of as much hypothesis
as proof. In the years following its initial characterization, TST-related
research has been primarily focused on the detoxification of cyanide as
well as biochemical and structural studies. The interaction with sulfur-
dependent antioxidants became the second point of focus, linking sulfur
metabolism directly to the detoxification of reactive oxygen species.
When researching positive predictors for diabetes and obesity, Morton
et al. [68] found TST to be singularly important to metabolic health.
Their study implies a link between TST activity and mitochondrial
health, thereby implicitly explaining the abundance of the enzyme.
From a clinical perspective, the implications for diabetes are para-
mount. The strength of the evidence linking enzymatic activity to po-
sitive clinical outcomes, makes TST a supremely interesting drug target.
The upregulation or artificial increase of TST activity would make sense
in familiar adiposity and diabetes. It is slightly surprising that the link
between TST and diabetes has not led to further published research
since 2016, given the strength of the evidence and implications to one
of the most affecting diseases of our time. For colonic diseases, the form
of association between disease progression and sulfurtransferase ac-
tivity warrants serious academical effort.
The diversity of cellular functions however creates interesting
pharmacological cross-roads. Finding an activating substance for TST
appears to be the most direct path to success. This might prove chal-
lenging however, seeing as efforts to provide structural analyses of the
enzyme have failed. In vivo there are also hampering physiological
circumstances in which e.g. NO mediated S-nitrosylation can cause
inactivation of TST [91]. The exceptional flexibility observed in human
TST might be inherent to its functions but will also complicate phar-
macological research. Elucidating the tertiary structure of hTST and
perhaps connecting the conformation to enzymatic function, might
significantly alleviate said efforts. Moreover, it is still unknown which
of the cellular functions (respiratory, anti-oxidant or other) provides the
protective effect against metabolic diseases. There is even a possibility
that the beneficial effect is not achieved through one function, but ra-
ther through the phosphorylative regulation of these functions. The
sulfur reactivity of TST may function as a gauge of mitochondrial ac-
tivity and the concomitant requirement of antioxidant and detoxifica-
tion activity. The nuance that this creates could be the key to its con-
tribution to mitochondrial health. As such, TST provides not one but
multiple pharmacological challenges. Finding the kinase/phosphatase
that governs TSTs phosphorylation state should be the primary focus
from an intercellular signaling perspective. It would also be supremely
interesting and helpful to examine the direct link between sulfur-
transferase activity and mitochondrial function.
Altogether, thiosulfate sulfurtransferase plays an important role in
mitochondrial health, linking sulfur metabolism to antioxidant and
respiratory function. The enzyme provides challenges to several fields,
and taking them on could not only improve the understanding of me-
tabolic diseases, it can also provide a way to treat them.
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